RisperidoneA Review of its Use in the Treatment of Bipolar Mania
作者:
Caroline Fenton,
Lesley J Scott,
期刊:
CNS Drugs
(ADIS Available online 2005)
卷期:
Volume 19,
issue 5
页码: 429-444
ISSN:1172-7047
年代: 2005
出版商: ADIS
关键词: Adis Drug Evaluations;Bipolar disorders, treatment;Risperidone, general
数据来源: ADIS
摘要:
Risperidone (Risperdal®) is an atypical antipsychotic with high affinity for 5-hydroxytryptamine (5-HT)2A, dopamine D2and α1- and α2-adrenergic receptors. Risperidone is now approved in the UK and the US for use in bipolar mania.Risperidone ≤6 mg/day, as monotherapy or adjunctive therapy with first-line mood stabilisers, significantly improves moderate and severe bipolar mania and improves global functioning over 3 weeks. Improvements in Young Mania Rating Scale (YMRS) scores in double-blind trials were greater with risperidone than with placebo over 3 weeks, and similar to those with haloperidol over 3 and 12 weeks. Risperidone was reasonably well tolerated. Limited data are available on the combination of risperidone and carbamazepine. Risperidone, as monotherapy or combined therapy with lithium or valproate semisodium, is an effective treatment option in bipolar mania.
点击下载:
PDF
(298KB)
返 回